Phagenesis, the world’s leading company in the treatment of
dysphagia, has expanded its Series B financing to $17 million. In 2011, Phagenesis announced a €7m Series B financing, led by Inventages Venture Capital. The increased resources will be used ...
[Published Pharma-Mag - May 22 2013]